Amiodarone: Historical development and pharmacologic profile (Q40156963)

18 September 2017

1 reference

title

Amiodarone: historical development and pharmacologic profile (English)

1 reference

18 September 2017

Amiodarone: Historical development and pharmacologic profile (English)

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

1 reference

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

author name string

B. N. Singh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6351575

5 October 2023

language of work or name

English

0 references

publication date

1 October 1983

1 reference

full work available at URL

18 September 2017

https://api.elsevier.com/content/article/PII:0002870383900029?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

https://api.elsevier.com/content/article/PII:0002870383900029?httpAccept=text/plain

5 October 2023

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

published in

American Heart Journal

1 reference

18 September 2017

volume

106

1 reference

18 September 2017

issue

4 Pt 2

1 reference

18 September 2017

page(s)

788-797

1 reference

New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil

18 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

New perspectives in the pharmacologic therapy of cardiac arrhythmias

5 October 2023

2

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

Q64869077

3

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Clinical efficacy of amiodarone as an antiarrhythmic agent

5 October 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

A NEW ADRENERGIC BETARECEPTOR ANTAGONIST

5 October 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Membrane calcium current in ventricular myocardial fibres

5 October 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Therapeutic implications of slow-channel blockade in cardiocirculatory disorders

5 October 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

Antifibrillatory action

11

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

5 October 2023

13

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death

5 October 2023

14

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

The effect of the cardiac membrane potential on the rapid availability of the sodium-carrying system

5 October 2023

15

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

The effect of altered thyroid state on atrial intracellular potentials

5 October 2023

16

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation

5 October 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

5 October 2023

18

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

The effect of the duration of the action potential on contraction in the mammalian heart muscle

5 October 2023

21

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone

5 October 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachy

5 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy

5 October 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

5 October 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone

5 October 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

JAUNDICE AND 'CARDIVIX'

28

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle

5 October 2023

31

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

The effects of amiodarone on the sinus node activity of the rabbit heart

5 October 2023

35

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Effects of amiodarone on thyroid function in patients with ischaemic heart disease

5 October 2023

36

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment

5 October 2023

37

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Hyperthyroxinemia with Bradycardia and Normal Thyrotropin Secretion after Chronic Amiodarone Administration*

5 October 2023

38

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials.

5 October 2023

39

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias

5 October 2023

40

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

The adrenergic antagonism of amiodarone

5 October 2023

42

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease

5 October 2023

43

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors

5 October 2023

45

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction

5 October 2023

46

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

Studies of amiodarone during experimental myocardial infarction: beneficial effects on hemodynamics and infarct size

5 October 2023

47

1 reference

https://api.crossref.org/works/10.1016/0002-8703(83)90002-9

5 October 2023

Identifiers

1 reference

18 September 2017

1 reference